Amedisys Inc  (AMED) Trade Now »     Rate AMED  -  Discuss AMED  -  Add to Watch List        

Filed under: Newsletters, Stocks to Buy, best stocks for 2010

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

J. Royden Ward is the editor of The Cabot Benjamin Graham Value Letter, a newsletter that -- as its name suggests -- focuses on stocks that meet the criteria of legendary value investor Ben Graham.

Filed under: Newsletters, Stocks to Buy

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"Amedisys (NASDAQ: AMED), a provider of home health services," notes Richard Moroney, whose Upside Stocks newsletter uses a quantitative system to select high growth, smaller cap issues.

"The company operates more than 500 locations, focuses on Medicare-eligible patients because of favorable reimbursement rates as well as a large and growing patient base.

Filed under: Pfizer (PFE), Newsletters, Johnson and Johnson (JNJ), Bristol-Myers Squibb (BMY), Stocks to Buy, Best Stocks for 2009

Health care has long been considered a recession-resistant business. Given the current economic challenges, it's little surprise that in our survey of favorite stocks for the coming year, a number of leading advisors turned to this classic defensive sector.

Growth to PE = 1.89 > undervalued

Price / Sales = 1.3 > reasonably valued

Sales growth 60% >growth in a bad economy

Earnings yield = 7.6% >pricing power intact

 AMED operates 261 Medicare-certified home health agencies and 14 Medicare-certified hospice agencies in 19 states.

So growth is high but with only 19 states covered it can reasonably grow @ 20% for 2-3 years. They are the fastest grower in their industry.  Potential buyout cnadidate.

"Amedisys (NASDAQ: AMED), one of the nation’s leading home health care companies, is a bear-proof stock," says David Fessler, a leading stock advisor and Oxford Club Advisory Panelist. 

He explains, "The stock is defying the market. It’s one of the best non-cyclical companies on the planet, which means it’s recession proof." here's his review.

" Amedisys has more than 8,000 caregivers, working from more than 350 home health centers and hospice agencies, across more than 30 states. These centers typically serve residents within a 50-mile radius.

this afternoon and came across Amedisys (AMED) which is an old favorite of this blog. AMED is currently trading at $33.80, up $2.44 or 7.78% on the day. I do not own any shares of Amedisys nor do I have any options on this stock.

AMEDISYS (AMED) IS RATED A BUY